The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiomics to predict response to pembrolizumab in patients with advanced rare cancers.
 
Rivka R. Colen
No Relationships to Disclose
 
Sara Ahmed
No Relationships to Disclose
 
Nabil Elshafeey
No Relationships to Disclose
 
Daniel D. Karp
Consulting or Advisory Role - Black Beret Life Sciences
Research Funding - Phosplatin Therapeutics
Travel, Accommodations, Expenses - Phosplatin Therapeutics
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - TYME
Research Funding - ArQule (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Sarina Anne Piha-Paul
Research Funding - Abbvie (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Adaptimmune; Alphasights; Axiom Biotechnologies; Baxter; Bayer; Eisai; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Janssen; Medscape; Merrimack; Numab; Pfizer; Seagen; Takeda; Trieza Therapeutics
Research Funding - Abbvie; Adaptimmune; Amgen; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Fate Therapeutics; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; MOLOGEN; National Cancer Institute; Novartis; Pfizer; Seagen; Takeda
Travel, Accommodations, Expenses - Genmab; Loxo; miRNA Therapeutics
 
Timothy A Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - Atrin Pharmaceuticals; Calithera Biosciences; EMD Serono; Leidos Biomedical Research; Lilly; Pfizer; Tesaro
 
Siqing Fu
Research Funding - Anaeropharma (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Endocyte (Inst); Huya Bioscience International (Inst); Lilly (Inst); MacroGenics (Inst); Medivir (Inst); NeuPharma, Inc. (Inst); Novartis (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Takeda (Inst)
 
Apostolia Maria Tsimberidou
Honoraria - Covance; Genentech
Consulting or Advisory Role - Roche
Research Funding - Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
 
Bettzy Stephen
No Relationships to Disclose
 
Jing Gong
No Relationships to Disclose
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Kelun; Lilly/ImClone; Merck Sharp & Dohme; Novartis; Orion; Peptomyc; Pfizer; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; Novartis
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; Kyocera; Lilly; MedImmune; Merck; NCI; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences